Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.

NCT00748709 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
20
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Boehringer Ingelheim